RAMM PharmaXCNQ:RAMM Gross Margin % is 63.85% as of Jan. 2026, which is 240% above its 10-year median of 18.76. The stock has 4 warning signs investors should review. Among 937 Drug Manufacturers companies, RAMM Pharma ranks worse than 67.88% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. RAMM Pharma's Gross Profit for the
three
months ended in Jan. 2026 was C$0.14 Mil. RAMM Pharma's Revenue for the
three
months ended in Jan. 2026 was C$0.21 Mil. Therefore, RAMM Pharma's Gross Margin % for the quarter that ended in Jan. 2026 was 63.85%.
The historical rank and industry rank for RAMM Pharma's Gross Margin % or its related term are showing as below:
XCNQ:RAMM'
s Gross Margin % Range Over the Past 10 Years
Min: -0.19 Med: 18.76 Max: 40.63
Current: 38.3
During the past 8 years, the highestGross Margin % of RAMM Pharma was 40.63%. The lowest was -0.19%. And the median was 18.76%.
XCNQ:RAMM's Gross Margin % is ranked worse than 67.88% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs XCNQ:RAMM: 38.30
RAMM Pharma had a gross margin of 63.85% for the quarter that ended in Jan. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for RAMM Pharma was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
RAMM Pharma had a gross margin of 63.85% for the quarter that ended in Jan. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
RAMM Pharma Gross Margin % Related Terms
RAMM Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
RAMM Pharma (XCNQ:RAMM) has a Gross Margin % of 63.85% as of Jan. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on RAMM Pharma and its competitors. This is 240% above median its historical median of 18.76. According to the industry distribution chart, RAMM Pharma ranks #636 out of 937 companies in the Drug Manufacturers industry, placing it in the top 67.9%.
Is RAMM Pharma's Gross Margin % too high?
RAMM Pharma's current Gross Margin % of 63.85% is 240% above median its 10-year median of 18.76. The Drug Manufacturers industry median Gross Margin % is 48.46. RAMM Pharma's value of 63.85% is 31.8% above this industry median. Based on the distribution chart, RAMM Pharma ranks #636 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does RAMM Pharma's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #636 out of 937 companies for Gross Margin %. This places RAMM Pharma in the lower half of its industry. The industry median Gross Margin % is 48.46. RAMM Pharma's value of 63.85% is 31.8% above this benchmark. While the company's 10-year median is 18.76 vs. the industry median of 48.46, RAMM Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RAMM Pharma's current Gross Margin % of 63.85% is 31.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current Gross Margin % is 63.85%, which is 240% above median its own 10-year median of 18.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Gross Margin % is 63.85%, which is 240% above median its 10-year median of 18.76 and 31.8% above the Drug Manufacturers industry median of 48.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Gross Margin % is 63.85% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 